Business Wire Industry News

Wednesday, September 22, 2021

Cyclica and IMPACT Therapeutics Team Up to Advance Differentiated Anti-cancer Drug Development

TORONTO & SHANGHAI--(BUSINESS WIRE)-- #biotech--Cyclica, the partner of choice for data-driven drug discovery, and IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics with synthetic lethality approach, announce today that they have entered to a collaboration agreement on IMPACT Therapeutics’ differentiated targeted anti-cancer drug development. IMPACT Therapeutics will apply Cyclica’s Ligand Express platform to selectively unders

Tuesday, September 21, 2021

PhenoTips Closes CAD $2.5M Funding Round Led by GreenSky Capital for Software to Transform Medical Genetics

TORONTO--(BUSINESS WIRE)-- #Funding--Genetics software startup PhenoTips® announced today that it has raised CAD $2.5 million in an oversubscribed seed fundraising round led by the GreenSky Accelerator Fund IV. This round includes the support of the Toronto Innovation Acceleration Partners, Thin Air Labs, Yorkville Partners, and angel investors including members of the GreenSky President’s Club. PhenoTips empowers healthcare providers to deliver precision medicine with the most complete and interoperable

Tuesday, September 21, 2021

Triumvira Announces First Patient with HER2-overexpressing Cancer Dosed with TAC-T Cell Therapy Using the Lonza Cocoon Platform

BASEL, Switzerland & MONTRÉAL & AUSTIN, Texas--(BUSINESS WIRE)--Lonza and Triumvira Immunologics ("Triumvira") announced that the first patient has been dosed with Triumvira's investigational T-cell antigen coupler (TAC-T cell) adoptive immunotherapy, TAC01-HER2, in development for the treatment of HER2-overexpressing cancers. Triumvira's TAC01-HER2, which harnesses natural T cell activation, was manufactured on Lonza's proprietary Cocoon® Platform at C3i Center Inc in Montréal, Canada. The Coc

Saturday, September 18, 2021

 Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion Group announced that the Korean Ministry of Food and Drug Safety (MFDS) approved regdanvimab (CT-P59), a monoclonal antibody treatment for COVID-19 for the extended use in elderly patients aged 50 years and over, or with at least one underlying medical condition (the obese, cardiovascular disease, chronic lung disease, diabetes, chronic kidney disease, chronic liver disease, and patients with immunosuppressive agents) with mild symptoms of COVID-

Friday, September 17, 2021

Bioscience Association Manitoba Announces Report Identifying Risks to the Supply Chain of PPE In Manitoba

WINNIPEG, Manitoba--(BUSINESS WIRE)--Bioscience Association Manitoba (BAM) announced the publication of a new report designed to identify and understand the risks to the supply chain for Personal Protective Equipment (PPE) in Manitoba. Data was collected from relevant respondents in two interview phases to gain a better insight into supply chain management risk mitigation for PPE masks in Manitoba. The first phase focused on health care and academia, while the second phase focused on business a

Friday, September 17, 2021

Perimeter Medical Imaging AI Announces its Participation in Multiple Upcoming Industry Conferences and Events

TORONTO--(BUSINESS WIRE)---- $PINK.V #AI--Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, announced today that it will participate in the following upcoming industry events and conferences: Dr. Anthony Lucci from the Department of Breast Surgical Oncology, Division of Surgery at MD Anderson Cancer

Thursday, September 16, 2021

Life Sciences BC Board of Directors Announcement

VANCOUVER, British Columbia--(BUSINESS WIRE)-- #BCbiotech--Following a well-attended AGM, Life Sciences BC is pleased to announce new members to its Board of Directors, with thanks to those who are departing.

Thursday, September 16, 2021

Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate and Durability in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that new clinical data for zanidatamab, a HER2‑targeted bispecific antibody, demonstrate promising response rates and durability in first-line HER2-positive GEA. These data were presented today by lead study investigator, Geoffrey Ku, M.D., Medical Oncologist at Memorial Sloan Kettering Cancer Center (MSK), at the ESMO

Wednesday, September 15, 2021

Aurinia Pharmaceuticals to Present at Upcoming September Investor Conferences

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the senior management team will present at the following upcoming virtual investor conferences: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Monday, September 20, 2021 at 2:55 pm ET. (access here) Cantor Global Healthcare Conference on September 30, 2021 at 12:40 pm ET. (access here) In order to participate in the audio webcasts, interested p